LifeMD Posts 43% Q4 Growth Amid SEC Restatement and GLP-1 Expansion

Introduction

LifeMD Inc. (NASDAQ: LFMD) is a publicly traded American telehealth company founded in 1994. The platform connects board-certified physicians and nurse practitioners with patients for virtual consultations, prescription management, and lab testing. LifeMD’s services include primary care, women’s health, hormone replacement therapy, weight management, and 24/7 urgent care, delivered through a HIPAA-compliant technology system.

Corporate Structure

LifeMD maintains an integrated network of clinicians, pharmacies, and diagnostic partners across all 50 states. The company employs between 201 and 500 professionals, including over 1,000 part-time MD/DO telehealth providers. Its infrastructure combines an affiliated medical group, pharmacy benefits manager, electronic health records, and a patient support call center.

Telehealth by National Cancer Institute

Developments and News

• March 10, 2025: LifeMD reported fourth-quarter 2024 results. Consolidated revenue increased 43% year-over-year to $64.3 million, primarily attributed to a 60% increase in telehealth revenue. Adjusted EBITDA reached $9.0 million, up 78%, while telehealth adjusted EBITDA was $5.9 million, up 396%. Net cash from operations doubled to $17.5 million, and the company ended the year with $35 million in cash. Management projected 2025 consolidated revenue between $265 million and $275 million and adjusted EBITDA of $30 million to $32 million.
• April 29, 2025: LifeMD began offering Novo Nordisk’s Wegovy through its virtual platform at reduced prices, extending cash-pay access to GLP-1 therapies.
• April 30, 2025: The company acquired Optimal Human Health MD to enhance its women’s health services, specifically in hormone, metabolism, and bone-density care.
• November 12, 2025: LifeMD filed a Form NT 10-Q, reporting $4.6 million in previous revenue over-recognition and notifying the SEC of the delay in its third-quarter financial statements.
• November 17, 2025: The company filed its quarterly report for the period ended September 30, 2025, and announced the sale of its majority stake in WorkSimpli Software, which refocuses on core virtual care and pharmacy services.

Financial and Strategic Analysis

As of November 18, 2025, LFMD shares traded at $3.5350, a decline of 25.26% on that day, with a trading volume of 2,215,575. The 52-week trading range is $3.46 to $15.84, and the market capitalization is approximately $220 million.
Profitability indicators reflect challenges: the trailing twelve-month EPS is –$0.20, with a net margin of –2.41% and a return on assets of –1.85%. Key financial ratios include Price/Sales at 0.81 and Enterprise Value/Revenue at 0.84. Recent operational metrics indicate:
• Telehealth subscribers totaled approximately 275,000 at year-end 2024, a 27% year-over-year increase.
• WorkSimpli subscribers totaled 164,000, with a sequential increase of 3,000.
• Gross margin for Q4 2024 was 85%, below the expected range of 88% to 90%, attributed to one-time pharmacy start-up costs.

Strategically, LifeMD is expanding its specialty care offerings in women’s health and behavioral health through acquisitions and partnerships. The GLP-1 weight management program seeks to improve access through pricing agreements with Novo Nordisk and LillyDirect. The sale of WorkSimpli allows the company to concentrate its resources on virtual medicine and pharmaceutical integration.

Market Position and Industry Context

The telehealth sector has experienced rapid growth, driven by consumer demand for convenient healthcare solutions and the increasing adoption of GLP-1 therapies. LifeMD competes with established virtual care providers and digital health startups. Its integrated model combines pharmacy benefits, diagnostic testing, and a broad clinical network. Anticipated regulatory changes, including Medicare coverage of GLP-1 medications expected following an April 1, 2025 launch, may increase patient enrollment in LifeMD's weight management program. However, the company faces ongoing challenges, including reimbursement complexities, data security issues, and competition for provider and patient engagement.

tl;dr

On November 12, 2025, LifeMD notified the SEC of a $4.6 million revenue overstatement and delayed its Q3 filing. On November 17, it completed the sale of its WorkSimpli stake. Earlier, on March 10, Q4 2024 revenue increased 43% to $64.3 million with adjusted EBITDA of $9.0 million, and management set a 2025 revenue guidance of $265 million to $275 million and adjusted EBITDA of $30 million to $32 million. In April 2025, partnerships with Novo Nordisk and LillyDirect aimed to enhance access to GLP-1 therapies, while the acquisition in April 2025 strengthened women's health services.